Clinical Trials

Genetic Frontiers Million Person Study
First Opinion

Community engagement is key to clinical trial recruitment and diversity

By Bobby Clark and Ronnie Tepp

Open vault
First Opinion

Move clinical trial data sharing from an option to an imperative

By Rebecca Li

Pink and blue capsules
First Opinion

Synthetic control arms can save time and money in clinical trials

By Jen Goldsack

Elderly hands
First Opinion

A new NIH rule won’t be enough to make clinical research more inclusive

By Louise Aronson

Real world clinical trial
First Opinion

Real-world evidence is changing the way we study drug safety and effectiveness

By Nancy A. Dreyer

Diversity in clinical trials concept
First Opinion

Diversity in clinical trials defines good science and better medicine

By Jane L. Delgado and Edward Abrahams

Health workers - Ebola - DRC
First Opinion

It isn’t crazy to conduct an Ebola clinical trial in a war zone — it’s necessary

By Jeremy Farrar

Pharmalot

Pharmalittle: Trump to require drug prices in ads; Europe cracks down on valsartan ingredients maker

By Ed Silverman

Futuristic medicine
First Opinion

How one pharmaceutical company is reinventing the clinical trial

By Andreas Koester

Locked file cabinet
First Opinion

All study participants have a right to know their own results. My lab has been doing that for years

By Julia G. Brody

Doctor using digital tablet
First Opinion

Digital technologies hold the key to streamlining and improving clinical trials

By Jake LaPorte

A doctor treats a patient at Wang Fu Hospital in Beijing.
First Opinion

China isn’t yet ready to conduct clinical trials for the pharma industry

By Anne Poli

Lessons Learned
Lessons Learned

Lessons Learned: This is how you take a public health degree to a startup and back to academia

By Megha Satyanarayana

Patient Advocacy Funding
Pharmalot

Millions in fines are adding up as clinical trial information goes unreported

By Ed Silverman

Kopy Katz
Adam's Take

Marinus Pharma finds the biotech imitation game can only last so long

By Adam Feuerstein

Acne
Biotech

Dermira discontinues development of acne drug after two late-stage trials fail

By Adam Feuerstein

neurological cognitive tests - Alzheimers
First Opinion

FDA’s updated standards remove an unnecessary barrier to testing Alzheimer’s drugs

By Howard M. Fillit

Jonathan Kimmelman
In the Lab

How well can you predict the outcome of clinical trials? Not as well as you may think

By Andrew Joseph

Medical syringe
Health

Unregulated herpes experiments expose ‘black hole’ of accountability

By Marisa Taylor — Kaiser Health News

Treadmill
First Opinion

Why did it take the CDC so long to reverse course on debunked treatments for chronic fatigue syndrome?

By Julie Rehmeyer and David Tuller

Streptococcus pneumoniae bacteria
Biotech

Nabriva novel antibiotic meets goals in late-stage bacterial pneumonia study

By Adam Feuerstein

John Maraganore
Business

Stakes are high as Alnylam awaits results from novel rare disease therapy

By Adam Feuerstein

Neurons
Business

5 things to know about Sage’s must-win drug trials in postpartum depression

By Adam Feuerstein

Tapeworm Cancer ChestXRay
Pharma

AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients

By Adam Feuerstein

Neurons
Biotech

7 things to know about Sage Therapeutics’ pivotal trial of a drug for severe epilepsy

By Adam Feuerstein

Chemo Drip
Biotech

Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions

By Adam Feuerstein

Cancer Care Costs
First Opinion

How do we solve the crisis in cancer communication?

By Lynn O'Connor Vos

Jesi Stracham
Health

Experimental scaffold hasn’t reversed her paralysis, but she’s embraced life ‘with wheels as legs’

By Rebecca Robbins

Cancer treatment
Gut Check

Do cancer clinical trials exaggerate the real-world benefits of drugs?

By Sharon Begley

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy